Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeurAxis, Inc. (NRXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. NeurAxis is a medical technology company focused on neuromodulation therapies, including its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and IB-Stim device for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older.
Through this page, users can review current and historical reports such as Form 8-K filings, which NeurAxis uses to announce material events. Recent 8-Ks describe FDA 510(k) clearance for expanded PENFS indications in patients aged 8 years and older, including adults, and outline the significance of this clearance as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in the adult patient population. Other 8-Ks detail capital markets activity, including an At The Market Offering Agreement under a shelf registration statement on Form S-3, preliminary financial estimates, and the termination of a license and collaboration agreement related to the NSS-2 Bridge device.
Investors can also use this filings page to monitor financing structures and equity programs, such as updates to the at-the-market offering capacity and the adoption of the NeurAxis, Inc. 2025 Employee Stock Purchase Plan. These documents explain how the company may issue common stock, the role of its sales agent, applicable commissions, and share limits under employee purchase arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of new 8-Ks, registration statements, and related exhibits. Real-time updates from EDGAR ensure that new NeurAxis filings appear promptly, while structured access to exhibits, legal opinions, and financial disclosures supports deeper analysis of the company’s regulatory, financing, and operational developments.
Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026. These equity awards were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan.
The RSUs vest in three equal annual installments over a three-year period, aligning Miranda’s compensation with longer-term company performance. After this grant, Miranda directly holds 47,569 derivative securities linked to Neuraxis common stock.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Watkins Bradley Mitchell received a grant of 21,598 shares of common stock on January 22, 2026, as compensation for serving as an independent director. The shares were valued at $4.63 each, bringing his directly held stake to 46,335 shares after the award.
Neuraxis, INC director granted shares as equity compensation. Director Jane Elizabeth Keyser acquired 21,598 shares of Neuraxis common stock on
After this award, she directly owns 46,335 common shares. According to the disclosure, these shares were issued as compensation for her services as an independent director, meaning this is a non-cash equity grant rather than a cash investment into the company’s stock.
Neuraxis, Inc. reported that its Chief Financial Officer, Timothy Robert Henrichs, acquired 75,231 restricted stock units (RSUs) on common stock as an equity award. The RSUs were granted at a reference value of $4.63 per share and will vest in three equal annual installments over a three-year period, aligning the CFO’s compensation with long-term shareholder interests. All 75,231 RSUs are held as direct ownership following this grant.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. Chief Executive Officer Brian Allen Carrico reported an award of 94,173 restricted stock units (RSUs) on common stock. The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
The RSUs vest in three equal annual installments over a three-year period, meaning portions of the award will be delivered over time if service-based conditions are met. This is an equity-based compensation grant, not an open-market share purchase or sale.
Neuraxis, Inc. 10% owner Brian P. Hannasch reported open-market purchases of the company’s common stock. He bought 40,000 shares on February 11, 2026 at a weighted average price of $4.65 per share and another 40,000 shares on February 12, 2026 at a weighted average price of $4.92 per share. Following these transactions, he directly beneficially owned 1,211,522 shares of Neuraxis common stock.
Neuraxis, Inc. received an updated Schedule 13G/A showing that investment entities linked to Michael Bigger hold a meaningful minority stake in its common stock. As of February 3, 2026, Bigger Capital Fund, LP beneficially owned 801,400 shares of common stock, or about 7.52% of the class.
District 2 Capital Fund LP beneficially owned 175,560 shares, or about 1.65%. Through his roles in these entities, Michael Bigger may be deemed to beneficially own a total of 976,960 shares, or roughly 9.17% of Neuraxis’ outstanding common stock, based on 10,652,812 shares outstanding as of November 7, 2025.
The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Neuraxis, indicating a passive investment stance under the Schedule 13G framework.
Neuraxis, Inc. director receives stock compensation. On 01/22/2026, the director was awarded 21,598 common shares at $4.63 per share as compensation for serving as an independent director. After this grant, the director beneficially owns 307,736 shares, including 286,138 shares held by Rosalind Master Fund L.P.
Neuraxis, Inc. director Kristin A. Ferge received 21,598 shares of common stock on January 22, 2026, reported as an "A" (acquired) transaction. The shares were issued at $4.63 per share as compensation for her services as an independent director. Following this grant, she directly owns 35,938 shares of Neuraxis common stock.
Neuraxis Inc. director Gil Aharon reported an indirect purchase of company stock. On 12/23/2025, an affiliate, Rosalind Master Fund L.P., purchased 286,138 common shares of Neuraxis at $3.52 per share, as disclosed in a Form 4 filing. The shares are held indirectly through Rosalind Advisors, Inc., which serves as advisor to Rosalind Master Fund L.P.
The filing notes that each reporting person disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest, meaning the economic exposure is limited to their financial stake in the fund rather than full ownership of all reported shares.